Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Efficacy Results Evaluating CPP-115 for the Treatment of Infantile Spasms

Catalyst Pharmaceutical Partners, Inc. CPRX today announced initial positive efficacy results from an investigator sponsored study of CPP-115 in an animal model of infantile spasms. In this study, CPP-115 significantly reduced observed spasms for three times longer than vigabatrin (the active ingredient in Lundbeck's Sabril®), which is currently approved for the treatment of infantile spasms. Further, CPP-115 was hundreds of times more potent than vigabatrin, exhibited less side effects, and with a larger margin of safety. Catalyst anticipates that the full data will be presented at a scientific meeting and will be submitted for publication in a peer reviewed journal. Steven R. Miller, Ph.D., Catalyst's Chief Scientific Officer and Chief Operating Officer, stated, "While these results are from an early-stage animal study, we believe that they support our view that CPP-115 may be an effective treatment for infantile spasms. The comparison of these results to the results of previously reported animal studies of vigabatrin tested in a similar model under similar circumstances leads us to believe that CPP-115 is very likely to be effective for the treatment of infantile spasms with higher potency than vigabatrin, and with a significantly improved side effects profile."